AZ876 is a liver X receptor (LXR) agonist.1,2 It activates LXRα and LXRβ in a transactivation assay in U2OS osteosarcoma cells (EC50 = 6 and 73 nM, respectively).1 AZ876 reduces phenylephrine-induced increases in cell size and protein synthesis in isolated neonatal rat ventricular myocytes.2 It decreases plasma cholesterol and VLDL levels and increases plasma triglyceride and HDL levels, as well as decreases the number and size of aortic root lesions in mice fed a Western diet in an APOE*3-Leiden transgenic mouse model of atherosclerosis when administered at a dose of 20 ?mol/kg.1
1.van der Hoorn, J.W.A., Lindén, D., Lindahl, U., et al.Low dose of the liver X receptor agonist, AZ876, reduces atherosclerosis in APOE*3Leiden mice without affecting liver or plasma triglyceride levelsBr. J. Pharmacol.162(7)1553-1563(2011) 2.Cannon, M.V., Yu, H., Candido, W.M., et al.The liver X receptor agonist AZ876 protects against pathological cardiac hypertrophy and fibrosis without lipogenic side effectsEur. J. Heart Fail.17(3)273-282(2015)